• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

More Senators question Allergans CEO on tribe patent deal

anonymous

Guest
n a letter to Allergan CEO Brent Saunders Tuesday, Sens. Sherrod Brown , D-Ohio; Maggie Hassan, D-N.H.; Amy Klobuchar , D-Minn.; Al Franken , D-Minn., and Patty Murray , D-Wash., requested documents and information about the deal, calling it a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis. "It is difficult to conceive of Allergan's transaction as anything other than a sham to subvert the existing intellectual property system," the senators wrote